Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Scholar Rock Holding Corp

NASDAQ: SRRK · Life Sciences · 5 alerts · CIK 1727196

Share price
$44.54Close, Nov 16
Market cap
$5.43B
Shares outstanding
122MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Scholar Rock Holding Corp filings on SEC EDGAR ↗

7:11 AM ET 8-K
Divestiture

Scholar Rock Holding Divestiture to BioNTech US Inc. for $205M

Scholar Rock agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to BioNTech US Inc. for $205 million in cash. The voucher was originally awarded by the FDA following the approval of ISEMBYLD for the treatment of spinal muscular atrophy. The transaction is subject to customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Act.

Value
$205M
Counterparty
BioNTech US Inc.

“The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA. We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
8:31 AM ET 8-K
Regulatory Approval

Scholar Rock Holding Regulatory Approval

Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.

8:01 AM ET 8-K
Regulatory Approval

Scholar Rock Holding Regulatory Approval

Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.

Earnings call
Sep 14, 2026, 8:00 AM ET

“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.